Biotech Values

[DewDiligence]

Retaane update from Alcon quarterly release:

[Retaane is evidently only quarter behind Macugen in the timing of the NDA submission. The last sentence of the excerpt below may be a case of “methinks he doth protest too much.” Why would Alcon bother to mention patient retention, a.k.a. dropouts, if there were not a problem in this regard?]

http://biz.yahoo.com/bw/040420/206245_1.html

>>
The ongoing Phase III clinical trial for Retaane(TM) is on track for its 12 month readout of data in September, with likely publication of that data around the American Academy of Ophthalmology annual meeting in October. This would be followed by the filing of a New Drug Application in the fourth quarter of 2004. Patient retention has been consistent with statistical expectations.
<<